Exact Mass: 790.4116

Exact Mass Matches: 790.4116

Found 103 metabolites which its exact mass value is equals to given mass value 790.4116, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

nostocyclopeptide A2

nostocyclopeptide A2

C40H54N8O9 (790.4014)


   

Relamorelin

4-({2-[(2-{[3-(1-benzothiophen-3-yl)-1-hydroxy-2-{[hydroxy(piperidin-3-yl)methylidene]amino}propylidene]amino}-1-hydroxy-3-(1H-indol-3-yl)propylidene)amino]-1-hydroxy-3-phenylpropylidene}amino)piperidine-4-carboximidate

C43H50N8O5S (790.3625)


   

[(2R,3S,4R,5R,6R)-2-(Hydroxymethyl)-4,5-bis[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-3-yl] dihydrogen phosphate

[(2R,3S,4R,5R,6R)-2-(Hydroxymethyl)-4,5-bis[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-3-yl] dihydrogen phosphoric acid

C34H68N2O14P2 (790.4146)


   

PA(20:4(5Z,8Z,11Z,14Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:4(5Z,8Z,11Z,14Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z-eicosatetraenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(5Z,8Z,11Z,14Z))

[(2R)-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(5Z,8Z,11Z,14Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 5Z,8Z,11Z,14Z-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:4(8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(8Z,11Z,14Z,17Z))

[(2R)-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGE2), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(PGE2/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGD2), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(PGD2/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:5(5Z,8Z,11Z,14Z,17Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/5-iso PGF2VI), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy]phosphonic acid

C43H67O11P (790.4421)


PA(5-iso PGF2VI/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Streptovirudin A1

Streptovirudin A1

C35H58N4O16 (790.3848)


   

Bishassanidin

Bishassanidin

C48H54O10 (790.3717)


   

Furostane base + 2O, O-Hex, O-Hex

Furostane base + 2O, O-Hex, O-Hex

C39H66O16 (790.4351)


Annotation level-3

   

Antibiotic TAN 1323D

Antibiotic TAN 1323D

C43H66O13 (790.4503)


   

anatolioside B

anatolioside B

C38H62O17 (790.3987)


   

22-deoxocucurbitoside B

22-deoxocucurbitoside B

C42H62O14 (790.4139)


   

(1beta,3beta,5beta,22alpha,25R)-26-O-beta-D-glucopyranosyl-furosta-1,3,5,22,26-pentaol-3-O-beta-D-glucoside

(1beta,3beta,5beta,22alpha,25R)-26-O-beta-D-glucopyranosyl-furosta-1,3,5,22,26-pentaol-3-O-beta-D-glucoside

C39H66O16 (790.4351)


   

1,2-Bis[4-(butoxycarbonyl)phenylamino]-1,2-bis[4-(butoxycarbonyl)phenylimino]ethane

1,2-Bis[4-(butoxycarbonyl)phenylamino]-1,2-bis[4-(butoxycarbonyl)phenylimino]ethane

C46H54N4O8 (790.3941)


   

Fusicoccin J-Pentaacetat

Fusicoccin J-Pentaacetat

C42H62O14 (790.4139)


   

(3beta,4beta,21beta,22alpha)-22-(acetyloxy)-3-(beta-D-glucopyranosyloxy)-23-hydroxy-21-{[(2Z)-2-methyl-1-oxobut-2-en-1-yl]oxy}-olean-12-en-28-oic acid|22-O-acetyl-21-O-angeloyl-3-O-beta-D-glucopyranosyl-24-hydroxyacerogenic acid|dipteroside E

(3beta,4beta,21beta,22alpha)-22-(acetyloxy)-3-(beta-D-glucopyranosyloxy)-23-hydroxy-21-{[(2Z)-2-methyl-1-oxobut-2-en-1-yl]oxy}-olean-12-en-28-oic acid|22-O-acetyl-21-O-angeloyl-3-O-beta-D-glucopyranosyl-24-hydroxyacerogenic acid|dipteroside E

C43H66O13 (790.4503)


   

spinosyn beta3

spinosyn beta3

C43H66O13 (790.4503)


   

1-beta-hydroxyatratogenin B 3-O-beta-D-cymaropyranosyl-(1->4)-alpha-L-diginopyranosyl-(1->4)-beta-D-cymaropyranoside|cynanoside R2

1-beta-hydroxyatratogenin B 3-O-beta-D-cymaropyranosyl-(1->4)-alpha-L-diginopyranosyl-(1->4)-beta-D-cymaropyranoside|cynanoside R2

C42H62O14 (790.4139)


   

tabernaricatine E

tabernaricatine E

C47H58N4O7 (790.4305)


   
   
   

Relamorelin

4-[[2-[[2-[[3-(1-benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide

C43H50N8O5S (790.3625)


C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C76358 - Growth Hormone-Releasing Hormone Analogue C78281 - Agent Affecting Musculoskeletal System > C1935 - Anticachexia Agent > C84868 - Ghrelin Peptide Analogue

   

N-((R)-3-(Benzo[b]thiophen-3-yl)-1-(((R)-1-(((S)-1-((4-carbamoylpiperidin-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)piperidine-4-carboxamide

N-((R)-3-(Benzo[b]thiophen-3-yl)-1-(((R)-1-(((S)-1-((4-carbamoylpiperidin-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)piperidine-4-carboxamide

C43H50N8O5S (790.3625)


C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C76358 - Growth Hormone-Releasing Hormone Analogue C78281 - Agent Affecting Musculoskeletal System > C1935 - Anticachexia Agent > C84868 - Ghrelin Peptide Analogue

   

[(2R,3S,4R,5R,6R)-2-(Hydroxymethyl)-4,5-bis[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-3-yl] dihydrogen phosphate

[(2R,3S,4R,5R,6R)-2-(Hydroxymethyl)-4,5-bis[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-3-yl] dihydrogen phosphoric acid

C34H68N2O14P2 (790.4146)


   

Bryostatin 16

Bryostatin 16

C42H62O14 (790.4139)


   

sucrose-2-(2-methyl)butyryl-3,4-di-(3-methyl)pentanoyl-1-(2-methyl)butyryl-6-acetyl-6-O-acetate

sucrose-2-(2-methyl)butyryl-3,4-di-(3-methyl)pentanoyl-1-(2-methyl)butyryl-6-acetyl-6-O-acetate

C38H62O17 (790.3987)


   

(2R,3S)-2-[[(3S,6S,9R,12S,15R)-3-benzyl-12-[(2S)-butan-2-yl]-6,7-dimethyl-2,5,8,11,14-pentaoxo-9-(2-phenylethyl)-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-methylpentanoate

(2R,3S)-2-[[(3S,6S,9R,12S,15R)-3-benzyl-12-[(2S)-butan-2-yl]-6,7-dimethyl-2,5,8,11,14-pentaoxo-9-(2-phenylethyl)-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-methylpentanoate

C42H60N7O8- (790.4503)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGE2)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGE2)

C43H67O11P (790.4421)


   

PA(PGE2/20:5(5Z,8Z,11Z,14Z,17Z))

PA(PGE2/20:5(5Z,8Z,11Z,14Z,17Z))

C43H67O11P (790.4421)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGD2)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/PGD2)

C43H67O11P (790.4421)


   

PA(PGD2/20:5(5Z,8Z,11Z,14Z,17Z))

PA(PGD2/20:5(5Z,8Z,11Z,14Z,17Z))

C43H67O11P (790.4421)


   

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/5-iso PGF2VI)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/5-iso PGF2VI)

C43H67O11P (790.4421)


   

PA(5-iso PGF2VI/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PA(5-iso PGF2VI/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C43H67O11P (790.4421)


   

PA(20:4(5Z,8Z,11Z,14Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(20:4(5Z,8Z,11Z,14Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C43H67O11P (790.4421)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(5Z,8Z,11Z,14Z))

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(5Z,8Z,11Z,14Z))

C43H67O11P (790.4421)


   

PA(20:4(8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(20:4(8Z,11Z,14Z,17Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C43H67O11P (790.4421)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(8Z,11Z,14Z,17Z))

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:4(8Z,11Z,14Z,17Z))

C43H67O11P (790.4421)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C43H67O11P (790.4421)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:5(5Z,8Z,11Z,14Z,17Z))

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H67O11P (790.4421)


   

1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-)

1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-)

C47H67O8P-2 (790.4573)


   

S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4-phosphopantetheine

S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4-phosphopantetheine

C38H67N2O11PS (790.4203)


An S-acyl-4-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4-phosphate with the carboxy group of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid.

   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C41H59O13P (790.3693)


   

1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-)

1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-)

C47H67O8P (790.4573)


A 1,2-diacyl-sn-glycero-3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)]-docosahexaenoyl-sn-glycero-3-phosphate; major species at pH 7.3.

   
   
   
   

PA 20:4/20:5;O3

PA 20:4/20:5;O3

C43H67O11P (790.4421)


   

PA 20:5/20:4;O3

PA 20:5/20:4;O3

C43H67O11P (790.4421)


   
   
   
   
   
   

PI P-18:1/11:4;O3

PI P-18:1/11:4;O3

C38H63O15P (790.3904)


   

PI P-18:1/12:3;O2

PI P-18:1/12:3;O2

C39H67O14P (790.4268)


   

PI 16:1/13:4;O2

PI 16:1/13:4;O2

C38H63O15P (790.3904)


   
   
   
   
   
   
   
   

9-(but-1-en-1-yl)-13-[(4,5-dimethoxy-6-methyloxan-2-yl)oxy]-3-hydroxy-14-methyl-2-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

9-(but-1-en-1-yl)-13-[(4,5-dimethoxy-6-methyloxan-2-yl)oxy]-3-hydroxy-14-methyl-2-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C43H66O13 (790.4503)


   

(7r)-5-hydroxy-7-[(3r)-5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

(7r)-5-hydroxy-7-[(3r)-5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

C48H54O10 (790.3717)


   

(2r,4as,4br,5s,7r,10ar)-5-hydroxy-7-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6s)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-2,4b-dimethyl-2-(2-methylfuran-3-yl)-3,4,4a,5,7,8,10,10a-octahydrophenanthrene-1,6-dione

(2r,4as,4br,5s,7r,10ar)-5-hydroxy-7-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6s)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-2,4b-dimethyl-2-(2-methylfuran-3-yl)-3,4,4a,5,7,8,10,10a-octahydrophenanthrene-1,6-dione

C42H62O14 (790.4139)


   

7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

C39H66O16 (790.4351)


   

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

C39H66O16 (790.4351)


   

(2e)-4-{[(2r,4r,5s,6r)-2-[(2s,3r,4s)-4-[(2r,3s,4e,6e,9r,10s,11s,12r,13r,14e,16z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-[(1e)-prop-1-en-1-yl]oxan-4-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4r,5s,6r)-2-[(2s,3r,4s)-4-[(2r,3s,4e,6e,9r,10s,11s,12r,13r,14e,16z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-[(1e)-prop-1-en-1-yl]oxan-4-yl]oxy}-4-oxobut-2-enoic acid

C43H66O13 (790.4503)


   

(2s,3s,3as,5ar,5bs,9r,13s,14r,16as,16bs)-9-[(1e)-but-1-en-1-yl]-13-{[(2r,4r,5r,6r)-4,5-dimethoxy-6-methyloxan-2-yl]oxy}-3-hydroxy-14-methyl-2-{[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

(2s,3s,3as,5ar,5bs,9r,13s,14r,16as,16bs)-9-[(1e)-but-1-en-1-yl]-13-{[(2r,4r,5r,6r)-4,5-dimethoxy-6-methyloxan-2-yl]oxy}-3-hydroxy-14-methyl-2-{[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C43H66O13 (790.4503)


   

16-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

16-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C42H62O14 (790.4139)


   

(1s,2s,4r,6s,8s,9r,10r,13r,14r)-16-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6s,8s,9r,10r,13r,14r)-16-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C42H62O14 (790.4139)


   

(2s,5r,8s,11s,14s,15r)-4,13,17-trihydroxy-2,11-diisopropyl-5,8-bis[(4-methoxyphenyl)methyl]-6,9,14-trimethyl-15-propyl-20-thia-3,6,9,12,16,21-hexaazabicyclo[16.2.1]henicosa-1(21),3,12,16,18-pentaene-7,10-dione

(2s,5r,8s,11s,14s,15r)-4,13,17-trihydroxy-2,11-diisopropyl-5,8-bis[(4-methoxyphenyl)methyl]-6,9,14-trimethyl-15-propyl-20-thia-3,6,9,12,16,21-hexaazabicyclo[16.2.1]henicosa-1(21),3,12,16,18-pentaene-7,10-dione

C42H58N6O7S (790.4087)


   

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-2,6-dimethyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-2,6-dimethyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

C38H62O17 (790.3987)


   

5-hydroxy-7-{[5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-2,4b-dimethyl-2-(2-methylfuran-3-yl)-3,4,4a,5,7,8,10,10a-octahydrophenanthrene-1,6-dione

5-hydroxy-7-{[5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-2,4b-dimethyl-2-(2-methylfuran-3-yl)-3,4,4a,5,7,8,10,10a-octahydrophenanthrene-1,6-dione

C42H62O14 (790.4139)


   

5-hydroxy-7-[5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

5-hydroxy-7-[5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

C48H54O10 (790.3717)


   

(1s,2s,4r,6r,8s,9s,10r,13r,14s)-16-{[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

(1s,2s,4r,6r,8s,9s,10r,13r,14s)-16-{[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C42H62O14 (790.4139)


   

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-7,9,13-trimethyl-6-[(3s)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14r,16s,18s)-7,9,13-trimethyl-6-[(3s)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,14,18-triol

C39H66O16 (790.4351)


   

(1s,3s,5z,7r,8e,13e,15s,17r,21r,23r,25s)-1,21-dihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacosa-8,11-dien-25-yl 2,2-dimethylpropanoate

(1s,3s,5z,7r,8e,13e,15s,17r,21r,23r,25s)-1,21-dihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacosa-8,11-dien-25-yl 2,2-dimethylpropanoate

C42H62O14 (790.4139)


   

4-(acetyloxy)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-[(2-methylbut-2-enoyl)oxy]-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

4-(acetyloxy)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-[(2-methylbut-2-enoyl)oxy]-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C43H66O13 (790.4503)


   

25-hydroxy-4,20-bis(3-hydroxy-2-methylhex-4-en-2-yl)-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

25-hydroxy-4,20-bis(3-hydroxy-2-methylhex-4-en-2-yl)-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

C44H58N2O11 (790.404)


   

(1r,1's,2r,2''r,4as,4''as,6s,6''s,7r,7''r,8as,8''as,13's,17'r,23's)-2,2'',5,5,5'',5'',8a,8''a-octamethyl-3,3'',4,4'',4a,4''a,6,6'',7,7'',8,8''-dodecahydro-2h,2''h-dispiro[naphthalene-1,5'-[4,12,16,24]tetraoxahexacyclo[11.10.1.0²,¹⁰.0³,⁷.0¹⁴,²².0¹⁵,¹⁹]tetracosane-17',1''-naphthalene]-2',7',9',14',19',21'-hexaene-6,6'',7,7'',8',20',23'-heptol

(1r,1's,2r,2''r,4as,4''as,6s,6''s,7r,7''r,8as,8''as,13's,17'r,23's)-2,2'',5,5,5'',5'',8a,8''a-octamethyl-3,3'',4,4'',4a,4''a,6,6'',7,7'',8,8''-dodecahydro-2h,2''h-dispiro[naphthalene-1,5'-[4,12,16,24]tetraoxahexacyclo[11.10.1.0²,¹⁰.0³,⁷.0¹⁴,²².0¹⁵,¹⁹]tetracosane-17',1''-naphthalene]-2',7',9',14',19',21'-hexaene-6,6'',7,7'',8',20',23'-heptol

C46H62O11 (790.4292)


   

(3r,4r,4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-4-(acetyloxy)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-{[(2z)-2-methylbut-2-enoyl]oxy}-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(3r,4r,4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-4-(acetyloxy)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-{[(2z)-2-methylbut-2-enoyl]oxy}-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C43H66O13 (790.4503)


   

(7s)-5-hydroxy-7-[(3s)-5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

(7s)-5-hydroxy-7-[(3s)-5-hydroxy-2,2-dimethyl-7,10-bis(2-methylbut-3-en-2-yl)-4,8-dioxo-3h-pyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)-7h-pyrano[3,2-g]chromene-2,6-dione

C48H54O10 (790.3717)


   

(4r,6e,8e,10e,12r,20s,22z,24r,25s,26e,28z)-25-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

(4r,6e,8e,10e,12r,20s,22z,24r,25s,26e,28z)-25-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

C44H58N2O11 (790.404)


   

(4s,6z,8z,10e,12r,20r,22z,24r,25s,26e,28z)-25-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

(4s,6z,8z,10e,12r,20r,22z,24r,25s,26e,28z)-25-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-12,24-dimethoxy-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,14(34),16,22,26,28,30(33)-decaene-2,18-dione

C44H58N2O11 (790.404)


   

16-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

16-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-8-hydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C42H62O14 (790.4139)


   

3-[3-benzyl-1,7,10,13,16-pentahydroxy-18-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-22-methyl-19-oxo-15-(sec-butyl)-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-12-yl]propanimidic acid

3-[3-benzyl-1,7,10,13,16-pentahydroxy-18-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-22-methyl-19-oxo-15-(sec-butyl)-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-12-yl]propanimidic acid

C40H54N8O9 (790.4014)


   

4,13,17-trihydroxy-2,11-diisopropyl-5,8-bis[(4-methoxyphenyl)methyl]-6,9,14-trimethyl-15-propyl-20-thia-3,6,9,12,16,21-hexaazabicyclo[16.2.1]henicosa-1(21),3,12,16,18-pentaene-7,10-dione

4,13,17-trihydroxy-2,11-diisopropyl-5,8-bis[(4-methoxyphenyl)methyl]-6,9,14-trimethyl-15-propyl-20-thia-3,6,9,12,16,21-hexaazabicyclo[16.2.1]henicosa-1(21),3,12,16,18-pentaene-7,10-dione

C42H58N6O7S (790.4087)


   

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 2,6-dimethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 2,6-dimethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

C38H62O17 (790.3987)


   

(2e)-n-[(2r,3s,4s,5s,6r)-2-{[(2s,3s,4r,5s,6s)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[(2r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxo-5,6-dihydropyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-10-methylundec-2-enimidic acid

(2e)-n-[(2r,3s,4s,5s,6r)-2-{[(2s,3s,4r,5s,6s)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[(2r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxo-5,6-dihydropyrimidin-1-yl)oxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-10-methylundec-2-enimidic acid

C35H58N4O16 (790.3848)


   

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-2,6-dimethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-2,6-dimethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octa-2,7-dienoate

C38H62O17 (790.3987)


   

(1s,3s,5z,7r,8e,13z,15s,17r,21r,23r,25s)-1,21-dihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacosa-8,11-dien-25-yl 2,2-dimethylpropanoate

(1s,3s,5z,7r,8e,13z,15s,17r,21r,23r,25s)-1,21-dihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacosa-8,11-dien-25-yl 2,2-dimethylpropanoate

C42H62O14 (790.4139)